Clinical trial
High-Dose Methotrexate in Treating Young Patients With Residual Ependymoma
NCT00287924 · Children's Cancer and Leukaemia Group, Other · Unknown status
Key facts
| NCT number | NCT00287924 |
|---|---|
| Title | High-Dose Methotrexate in Treating Young Patients With Residual Ependymoma |
| Official title | Phase II Study of High-Dose Methotrexate in Children With Residual Ependymoma |
| Lead sponsor | Children's Cancer and Leukaemia Group, Other |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors |
| Intervention type | Drug, Procedure |
| Interventions | methotrexate, adjuvant therapy |
| Enrollment | 29 |
| Start date | Mar 1, 2005 |
| Primary completion | Mar 1, 2010 |
| First posted | Feb 7, 2006 |
| Last update posted | Sep 17, 2013 |
| Countries | Ireland, United Kingdom |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: